SAGE Therapeutics Inc. (SAGE)

106.02
5.40 5.40
NASDAQ : Health Technology
Prev Close 100.62
Open 100.00
Day Low/High 100.00 / 106.19
52 Wk Low/High 100.16 / 195.97
Volume 90.27K
Avg Volume 404.70K
Exchange NASDAQ
Shares Outstanding 46.89M
Market Cap 5.19B
EPS -7.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sage Therapeutics Receives Notification Of PDUFA Extension For ZULRESSO™ (brexanolone) Injection

Sage Therapeutics Receives Notification Of PDUFA Extension For ZULRESSO™ (brexanolone) Injection

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Notable Tuesday Option Activity: SAGE, REN, TSLA

Notable Tuesday Option Activity: SAGE, REN, TSLA

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sage Therapeutics Inc , where a total of 4,861 contracts have traded so far, representing approximately 486,100 underlying shares. That amounts to about 101.3% of SAGE's average daily trading volume over the past month of 479,955 shares.

Sage Therapeutics To Present At Stifel 2018 Healthcare Conference

Sage Therapeutics To Present At Stifel 2018 Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Stifel 2018 Healthcare Conference...

Sage Therapeutics Announces Third Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics Announces Third Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the third quarter...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November 1, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 In Support Of Benefit-Risk Profile Of ZULRESSO™ (brexanolone) Injection For Treatment Of Postpartum Depression

Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 In Support Of Benefit-Risk Profile Of ZULRESSO™ (brexanolone) Injection For Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss ZULRESSO™ (brexanolone) Injection For The Treatment Of Postpartum Depression

Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss ZULRESSO™ (brexanolone) Injection For The Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the company's common stock.

Sage Therapeutics Turned Down - Don't Rush to Be a Buyer

Sage Therapeutics Turned Down - Don't Rush to Be a Buyer

Let's see what the charts and indicators look like.

Red Hat, Take-Two Interactive, Sage Therapeutics: 'Mad Money' Lightning Round

Red Hat, Take-Two Interactive, Sage Therapeutics: 'Mad Money' Lightning Round

Jim Cramer weighs in on Red Hat, Take-Two Interactive, Sage Therapeutics, Mazor Robotics, Donnelly Financial Solutions.

Untangling the Spin: Cramer's 'Mad Money' Recap (Thursday 10/25/18)

Untangling the Spin: Cramer's 'Mad Money' Recap (Thursday 10/25/18)

Jim Cramer says investors need context about what's really happening with earnings, tariffs, the Fed, and in Washington.

Noteworthy Wednesday Option Activity: SAGE, BERY, LOB

Noteworthy Wednesday Option Activity: SAGE, BERY, LOB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sage Therapeutics Inc , where a total volume of 1,657 contracts has been traded thus far today, a contract volume which is representative of approximately 165,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42% of SAGE's average daily trading volume over the past month, of 394,205 shares.

Sage Therapeutics To Report Third Quarter 2018 Financial Results On Tuesday, November 6, 2018

Sage Therapeutics To Report Third Quarter 2018 Financial Results On Tuesday, November 6, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on October 1, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Present At Morgan Stanley 16th Annual Global Healthcare Conference

Sage Therapeutics To Present At Morgan Stanley 16th Annual Global Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Morgan Stanley 16th Annual Global...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on September 4, 2018, the Compensation Committee of Sage's Board...

Sage Therapeutics Announces The Lancet Publishes Integrated Data From Pivotal Trials For Brexanolone Injection In Postpartum Depression

Sage Therapeutics Announces The Lancet Publishes Integrated Data From Pivotal Trials For Brexanolone Injection In Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced The Lancet has published an integrated analysis across three,...

Sage Therapeutics Announces Second Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics Announces Second Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the second quarter...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Present At Canaccord 38th Annual Growth Conference

Sage Therapeutics To Present At Canaccord 38th Annual Growth Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Canaccord 38th Annual Growth...

Sage Therapeutics To Report Second Quarter 2018 Financial Results On Tuesday, August 7, 2018

Sage Therapeutics To Report Second Quarter 2018 Financial Results On Tuesday, August 7, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018, the Compensation Committee of Sage's Board of...

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sage Therapeutics, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sage Therapeutics, Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

NEW YORK, June 25, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Sage...

Sage Therapeutics And Shionogi & Co., Ltd., Enter Strategic Collaboration To Develop And Commercialize SAGE-217 For MDD And Other Indications In Japan, Taiwan And South Korea

Sage Therapeutics And Shionogi & Co., Ltd., Enter Strategic Collaboration To Develop And Commercialize SAGE-217 For MDD And Other Indications In Japan, Taiwan And South Korea

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, and Shionogi & Co.

Jim Cramer: Investors Pull Into the FANG Rest Stop

Jim Cramer: Investors Pull Into the FANG Rest Stop

When rotations slow or pause, investors return to the new classics.

Sage Announces Pivotal Phase 3 Trial Status For SAGE-217 In Major Depressive Disorder And Postpartum Depression Based On FDA Breakthrough Therapy Meeting

Sage Announces Pivotal Phase 3 Trial Status For SAGE-217 In Major Depressive Disorder And Postpartum Depression Based On FDA Breakthrough Therapy Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced its expedited development plan for SAGE-217 following a Breakthrough...

Sage Therapeutics To Present At Goldman Sachs 39th Annual Global Healthcare Conference

Sage Therapeutics To Present At Goldman Sachs 39th Annual Global Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 39 th Annual Global...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 1, 2018, the Compensation Committee of Sage's Board of...

Noteworthy Wednesday Option Activity: SAGE, SAM, EXPR

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sage Therapeutics Inc , where a total of 1,736 contracts have traded so far, representing approximately 173,600 underlying shares. That amounts to about 45.2% of SAGE's average daily trading volume over the past month of 383,805 shares.